See what’s new.
Oak Ridge National Laboratory Collaborates with IonQ to Drive Critical U.S. Infrastructure Improvements
ORNL will leverage Duke start-up IonQ’s quantum technology to help solve power grid challenges in the U.S.
The Power and Promise of RNA
Several Duke researchers studying RNA modification are profiled in this Magnify article from the School of Medicine. Tech available for licensing!
Transforming inventions into products: Duke charts a path for student innovators
Duke’s innovation ecosystem collaborates to offer Duke graduate and professional students a hands-on technology commercialization bootcamp – focused on student-led inventions.
BMI OrganBank, Atrium Health and LifeShare Carolinas Partner to Launch Nation’s First Organ Banking Technology
BMI OrganBank licensed perfusion tech from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig (Surgery, SOM).
Duke is Inventive: A Century of Innovation at Duke University
A new Centennial physical and digital exhibit from OTC collects innovations, inventors, and companies spinning out of Duke University.
Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.
Neurophos Raises $7.2 Million Round to Create Super-fast, Energy-Efficient Metamaterial-Based Optical AI Chips for Data Centers
Neurophos is a metamaterial-based start-up developing optical computing chips. It was founded by PhD graduate Patrick Bowen and spun out of the lab of Professor David Smith (ECE, Pratt).
Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim
Ten63 is a Duke University start-up and DCP portfolio company out of the lab of Professor Bruce Donald (Computer Science, Trinity).
Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics is a Duke start-up and DCP portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).